Lyon: Raises the target price of SKB BIO-B (06990) to HKD 626.4, with first-half net profit exceeding expectations.
The company is introducing a new mode of cancer treatment, and the global launch of sac-TMT before 2027 remains a key catalyst for the future.
Lyon released a research report stating that SKB BIO-B (06990) saw a 2.9% year-on-year revenue increase in the first half of the year, with commercial income experiencing a strong year-on-year growth of 112.1% due to the expansion of indications and distribution channels for sac-TMT. Net profit reached 388 million yuan, exceeding market expectations. The bank has included the performance in its new forecast and raised the target price from HKD 500.7 to HKD 626.4. The "outperform" rating remains unchanged.
The report pointed out that Kelun Biotech's management has maintained its full-year sales guidance for 2026, expecting commercial revenue to at least double compared to 2025. The company is introducing a new model of cancer treatment, and the global launch of sac-TMT before 2027 remains a key catalyst for the future.
Related Articles
BINJIANG SER (03316) will distribute a mid-term dividend of HKD 0.922 per share on January 28, 2027.
CICC (03908) will issue perpetual subordinated bonds (Fifth Series) with a coupon rate of 1.90% for professional investors in 2026.
BINJIANG SER (03316) announced its interim results, with a net profit attributable to equity shareholders of approximately 315 million yuan, an increase of 5.8% year-on-year.
BINJIANG SER (03316) will distribute a mid-term dividend of HKD 0.922 per share on January 28, 2027.
CICC (03908) will issue perpetual subordinated bonds (Fifth Series) with a coupon rate of 1.90% for professional investors in 2026.
BINJIANG SER (03316) announced its interim results, with a net profit attributable to equity shareholders of approximately 315 million yuan, an increase of 5.8% year-on-year.
RECOMMEND
